The FDA approved the Dako Omnis panel to identify patients with colorectal cancer with mismatch repair deficiency. The mismatch repair immunohistochemical panel pharmDx (Dako Omnis) has received U.S.
Initial Dose Adjustment of Zolbetuximab Plus Chemotherapy in CLDN18.2-Positive Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer (GENTLE-Z), a Randomized, Phase II Trial ...
Please provide your email address to receive an email when new articles are posted on . Patients with stage III deficient mismatch repair colon cancer derived significant benefit from the addition of ...
The prognostic factors for refractory metastatic colorectal cancer treated with trifluridine–tipiracil. MSI-H : Microsatellite instability High. dMMR : Mismatch repair deficient. RCT : Randomised ...
Colon cancer is the third most prevalent form of cancer in the U.S., and while screening has helped detect and prevent colon cancer from spreading, major advancements in treating colon cancer have ...
Colorectal cancer has long baffled scientists because, unlike most tumors, patients often do better when their cancers are ...
CHICAGO -- The risk of recurrence or death after surgery for deficient mismatch repair (dMMR) colon cancer decreased by 50% in patients who received immunotherapy in addition to adjuvant chemotherapy, ...
ABT-301, an HDAC1/2/3 inhibitor, enhances immune response and tumor microenvironment, potentially improving immune checkpoint inhibitor efficacy in metastatic colorectal cancer. The phase 1/2 trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results